Related Experiment Video
Updated: Jul 9, 2025
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Exploring ceRNA networks for key biomarkers in breast cancer subtypes and immune regulation
Alireza Shariatmadar Taleghani1, Yasaman Zohrab Beigi1, Fatemeh Zare-Mirakabad2
1Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Abstract:
Breast cancer is a major global health concern, and recent researches have highlighted the critical roles of non-coding RNAs in both cancer and the immune system. The competing endogenous RNA hypothesis suggests that various types of RNA, including coding and non-coding RNAs, compete for microRNA targets, acting as molecular sponges. This study introduces the Pre_CLM_BCS pipeline to investigate the potential of long non-coding RNAs and circular RNAs as biomarkers in breast cancer subtypes. The pipeline identifies specific modules within each subtype that contain at least one long non-coding RNA or circular RNA exhibiting significantly distinct expression patterns when compared to other subtypes. The results reveal potential biomarker genes for each subtype, such as circ_001845, circ_001124, circ_003925, circ_000736, and circ_003996 for the basal-like subtype, circ_00306 and circ_00128 for the luminal B subtype, circ_000709 and NPHS1 for the normal-like subtype, CAMKV and circ_001855 for the luminal A subtype, and circ_00128 and circ_00173 for the HER2+ subtype. Additionally, certain long non-coding RNAs and circular RNAs, including RGS5-AS1, C6orf223, HHLA3-AS1, circ_000349, circ_003996, circ_003925, circ_002665, circ_001855, and DLEU1, are identified as potential regulators of T cell mechanisms, underscoring their importance in understanding breast cancer progression in various subtypes. This pipeline provides valuable insights into cancer and immune-related processes in breast cancer subtypes.
Insights
This study introduces a new pipeline to identify long non-coding RNAs and circular RNAs as breast cancer biomarkers. These non-coding RNAs show distinct expression patterns across subtypes and may regulate immune responses.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Breast cancer is a significant global health issue.
- Non-coding RNAs play crucial roles in cancer and immunity.
- The competing endogenous RNA hypothesis explains RNA interactions.
Purpose of the Study:
- To develop a pipeline (Pre_CLM_BCS) for identifying long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) as biomarkers in breast cancer subtypes.
- To investigate the differential expression of lncRNAs and circRNAs across breast cancer subtypes.
- To explore the potential role of these non-coding RNAs in regulating immune mechanisms within breast cancer.
Main Methods:
- Development of the Pre_CLM_BCS pipeline.
- Identification of specific RNA modules within each breast cancer subtype.
- Analysis of differential expression patterns of lncRNAs and circRNAs compared to other subtypes.
- Assessment of potential regulatory roles in T cell mechanisms.
Main Results:
- Identification of subtype-specific potential biomarker lncRNAs and circRNAs (e.g., circ_001845 for basal-like, circ_00306 for luminal B, NPHS1 for normal-like, CAMKV for luminal A, circ_00173 for HER2+).
- Discovery of lncRNAs and circRNAs (e.g., RGS5-AS1, HHLA3-AS1, circ_003996) potentially regulating T cell mechanisms.
- The pipeline successfully identified distinct molecular signatures across breast cancer subtypes.
Conclusions:
- The Pre_CLM_BCS pipeline effectively identifies potential lncRNA and circRNA biomarkers for distinct breast cancer subtypes.
- Certain identified lncRNAs and circRNAs may play significant roles in regulating immune responses in breast cancer.
- These findings offer valuable insights into cancer and immune-related processes, aiding in understanding breast cancer progression.
